Abstract
Summary
The global market for Pharmacodynamic (PD) Biomarkers was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pharmacodynamic (PD) Biomarkers, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pharmacodynamic (PD) Biomarkers by region & country, by Type, and by Application.
The Pharmacodynamic (PD) Biomarkers market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacodynamic (PD) Biomarkers.
Market Segmentation
By Company
Thermo Fisher Scientific
Merck
Bio-Rad Laboratories
QIAGEN
Roche
Danaher Corporation
Siemens Healthcare
Abbott
Agilent Technologies
Segment by Type:
Exposure Biomarkers
Effect Biomarkers
Susceptibility Biomarkers
Segment by Application
Diagnostics
Drug Discovery
Personalized Medicine
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pharmacodynamic (PD) Biomarkers manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pharmacodynamic (PD) Biomarkers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pharmacodynamic (PD) Biomarkers in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pharmacodynamic (PD) Biomarkers, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pharmacodynamic (PD) Biomarkers by region & country, by Type, and by Application.
The Pharmacodynamic (PD) Biomarkers market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacodynamic (PD) Biomarkers.
Market Segmentation
By Company
Thermo Fisher Scientific
Merck
Bio-Rad Laboratories
QIAGEN
Roche
Danaher Corporation
Siemens Healthcare
Abbott
Agilent Technologies
Segment by Type:
Exposure Biomarkers
Effect Biomarkers
Susceptibility Biomarkers
Segment by Application
Diagnostics
Drug Discovery
Personalized Medicine
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pharmacodynamic (PD) Biomarkers manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pharmacodynamic (PD) Biomarkers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pharmacodynamic (PD) Biomarkers in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Pharmacodynamic (PD) Biomarkers Product Introduction
1.2 Global Pharmacodynamic (PD) Biomarkers Market Size Forecast
1.3 Pharmacodynamic (PD) Biomarkers Market Trends & Drivers
1.3.1 Pharmacodynamic (PD) Biomarkers Industry Trends
1.3.2 Pharmacodynamic (PD) Biomarkers Market Drivers & Opportunity
1.3.3 Pharmacodynamic (PD) Biomarkers Market Challenges
1.3.4 Pharmacodynamic (PD) Biomarkers Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Pharmacodynamic (PD) Biomarkers Players Revenue Ranking (2023)
2.2 Global Pharmacodynamic (PD) Biomarkers Revenue by Company (2019-2024)
2.3 Key Companies Pharmacodynamic (PD) Biomarkers Manufacturing Base Distribution and Headquarters
2.4 Key Companies Pharmacodynamic (PD) Biomarkers Product Offered
2.5 Key Companies Time to Begin Mass Production of Pharmacodynamic (PD) Biomarkers
2.6 Pharmacodynamic (PD) Biomarkers Market Competitive Analysis
2.6.1 Pharmacodynamic (PD) Biomarkers Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Pharmacodynamic (PD) Biomarkers Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacodynamic (PD) Biomarkers as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Exposure Biomarkers
3.1.2 Effect Biomarkers
3.1.3 Susceptibility Biomarkers
3.2 Global Pharmacodynamic (PD) Biomarkers Sales Value by Type
3.2.1 Global Pharmacodynamic (PD) Biomarkers Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Pharmacodynamic (PD) Biomarkers Sales Value, by Type (2019-2030)
3.2.3 Global Pharmacodynamic (PD) Biomarkers Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Diagnostics
4.1.2 Drug Discovery
4.1.3 Personalized Medicine
4.1.4 Others
4.2 Global Pharmacodynamic (PD) Biomarkers Sales Value by Application
4.2.1 Global Pharmacodynamic (PD) Biomarkers Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Pharmacodynamic (PD) Biomarkers Sales Value, by Application (2019-2030)
4.2.3 Global Pharmacodynamic (PD) Biomarkers Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Pharmacodynamic (PD) Biomarkers Sales Value by Region
5.1.1 Global Pharmacodynamic (PD) Biomarkers Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Pharmacodynamic (PD) Biomarkers Sales Value by Region (2019-2024)
5.1.3 Global Pharmacodynamic (PD) Biomarkers Sales Value by Region (2025-2030)
5.1.4 Global Pharmacodynamic (PD) Biomarkers Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Pharmacodynamic (PD) Biomarkers Sales Value, 2019-2030
5.2.2 North America Pharmacodynamic (PD) Biomarkers Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Pharmacodynamic (PD) Biomarkers Sales Value, 2019-2030
5.3.2 Europe Pharmacodynamic (PD) Biomarkers Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Pharmacodynamic (PD) Biomarkers Sales Value, 2019-2030
5.4.2 Asia Pacific Pharmacodynamic (PD) Biomarkers Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Pharmacodynamic (PD) Biomarkers Sales Value, 2019-2030
5.5.2 South America Pharmacodynamic (PD) Biomarkers Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Pharmacodynamic (PD) Biomarkers Sales Value, 2019-2030
5.6.2 Middle East & Africa Pharmacodynamic (PD) Biomarkers Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Pharmacodynamic (PD) Biomarkers Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Pharmacodynamic (PD) Biomarkers Sales Value
6.3 United States
6.3.1 United States Pharmacodynamic (PD) Biomarkers Sales Value, 2019-2030
6.3.2 United States Pharmacodynamic (PD) Biomarkers Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Pharmacodynamic (PD) Biomarkers Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Pharmacodynamic (PD) Biomarkers Sales Value, 2019-2030
6.4.2 Europe Pharmacodynamic (PD) Biomarkers Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Pharmacodynamic (PD) Biomarkers Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Pharmacodynamic (PD) Biomarkers Sales Value, 2019-2030
6.5.2 China Pharmacodynamic (PD) Biomarkers Sales Value by Type (%), 2023 VS 2030
6.5.3 China Pharmacodynamic (PD) Biomarkers Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Pharmacodynamic (PD) Biomarkers Sales Value, 2019-2030
6.6.2 Japan Pharmacodynamic (PD) Biomarkers Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Pharmacodynamic (PD) Biomarkers Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Pharmacodynamic (PD) Biomarkers Sales Value, 2019-2030
6.7.2 South Korea Pharmacodynamic (PD) Biomarkers Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Pharmacodynamic (PD) Biomarkers Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Pharmacodynamic (PD) Biomarkers Sales Value, 2019-2030
6.8.2 Southeast Asia Pharmacodynamic (PD) Biomarkers Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Pharmacodynamic (PD) Biomarkers Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Pharmacodynamic (PD) Biomarkers Sales Value, 2019-2030
6.9.2 India Pharmacodynamic (PD) Biomarkers Sales Value by Type (%), 2023 VS 2030
6.9.3 India Pharmacodynamic (PD) Biomarkers Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Thermo Fisher Scientific
7.1.1 Thermo Fisher Scientific Profile
7.1.2 Thermo Fisher Scientific Main Business
7.1.3 Thermo Fisher Scientific Pharmacodynamic (PD) Biomarkers Products, Services and Solutions
7.1.4 Thermo Fisher Scientific Pharmacodynamic (PD) Biomarkers Revenue (US$ Million) & (2019-2024)
7.1.5 Thermo Fisher Scientific Recent Developments
7.2 Merck
7.2.1 Merck Profile
7.2.2 Merck Main Business
7.2.3 Merck Pharmacodynamic (PD) Biomarkers Products, Services and Solutions
7.2.4 Merck Pharmacodynamic (PD) Biomarkers Revenue (US$ Million) & (2019-2024)
7.2.5 Merck Recent Developments
7.3 Bio-Rad Laboratories
7.3.1 Bio-Rad Laboratories Profile
7.3.2 Bio-Rad Laboratories Main Business
7.3.3 Bio-Rad Laboratories Pharmacodynamic (PD) Biomarkers Products, Services and Solutions
7.3.4 Bio-Rad Laboratories Pharmacodynamic (PD) Biomarkers Revenue (US$ Million) & (2019-2024)
7.3.5 QIAGEN Recent Developments
7.4 QIAGEN
7.4.1 QIAGEN Profile
7.4.2 QIAGEN Main Business
7.4.3 QIAGEN Pharmacodynamic (PD) Biomarkers Products, Services and Solutions
7.4.4 QIAGEN Pharmacodynamic (PD) Biomarkers Revenue (US$ Million) & (2019-2024)
7.4.5 QIAGEN Recent Developments
7.5 Roche
7.5.1 Roche Profile
7.5.2 Roche Main Business
7.5.3 Roche Pharmacodynamic (PD) Biomarkers Products, Services and Solutions
7.5.4 Roche Pharmacodynamic (PD) Biomarkers Revenue (US$ Million) & (2019-2024)
7.5.5 Roche Recent Developments
7.6 Danaher Corporation
7.6.1 Danaher Corporation Profile
7.6.2 Danaher Corporation Main Business
7.6.3 Danaher Corporation Pharmacodynamic (PD) Biomarkers Products, Services and Solutions
7.6.4 Danaher Corporation Pharmacodynamic (PD) Biomarkers Revenue (US$ Million) & (2019-2024)
7.6.5 Danaher Corporation Recent Developments
7.7 Siemens Healthcare
7.7.1 Siemens Healthcare Profile
7.7.2 Siemens Healthcare Main Business
7.7.3 Siemens Healthcare Pharmacodynamic (PD) Biomarkers Products, Services and Solutions
7.7.4 Siemens Healthcare Pharmacodynamic (PD) Biomarkers Revenue (US$ Million) & (2019-2024)
7.7.5 Siemens Healthcare Recent Developments
7.8 Abbott
7.8.1 Abbott Profile
7.8.2 Abbott Main Business
7.8.3 Abbott Pharmacodynamic (PD) Biomarkers Products, Services and Solutions
7.8.4 Abbott Pharmacodynamic (PD) Biomarkers Revenue (US$ Million) & (2019-2024)
7.8.5 Abbott Recent Developments
7.9 Agilent Technologies
7.9.1 Agilent Technologies Profile
7.9.2 Agilent Technologies Main Business
7.9.3 Agilent Technologies Pharmacodynamic (PD) Biomarkers Products, Services and Solutions
7.9.4 Agilent Technologies Pharmacodynamic (PD) Biomarkers Revenue (US$ Million) & (2019-2024)
7.9.5 Agilent Technologies Recent Developments
8 Industry Chain Analysis
8.1 Pharmacodynamic (PD) Biomarkers Industrial Chain
8.2 Pharmacodynamic (PD) Biomarkers Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Pharmacodynamic (PD) Biomarkers Sales Model
8.5.2 Sales Channel
8.5.3 Pharmacodynamic (PD) Biomarkers Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer